Table 1 Summary statistics for patient age and disease characteristics in the development and two validation cohorts
Laviana 2020 | 1-year post | 2-year post | |
|---|---|---|---|
N = 1402 | N = 669 | N = 439 | |
Age (years) | |||
Mean (SD) | 65.4 (6.3) | 65.1 (6.2) | |
Median (range) | 62 (57, 66) | 66 (41, 78) | 66 (41, 78) |
Missing | 0% (0) | 2% (15) | 2% (8) |
Gleason score | |||
≤6 | 52% (723) | 12% (82) | 10% (44) |
3 + 4 | 30% (413) | 49% (329) | 50% (220) |
4 + 3 | 10% (145) | 22% (150) | 21% (93) |
≥8 | 8% (117) | 16% (105) | 18% (81) |
Missing | < 1% (4) | < 1% (3) | < 1% (1) |
Prostate specific antigen (ng/dL) | |||
0- < 4 | 23% (319) | 12% (77) | 11% (49) |
4- < 10 | 67% (933) | 53% (353) | 51% (222) |
10- < 20 | 8% (114) | 14% (94) | 17% (73) |
≥20 | 3% (36) | 2% (13) | 3% (11) |
Missing | 0% (0) | 20% (132) | 19% (84) |
Pathological T stage | |||
1–2 | 37% (245) | 35% (155) | |
3–4 | 50% (332) | 54% (237) | |
Missing | 14% (92) | 11% (47) | |
Pathological N and M stage | |||
N0, M0 | 40% (269) | 43% (187) | |
N1, M1 | 3% (19) | 3% (13)] | |
Missing | 57% (381) | 54% (239) | |
General health | |||
Fair | < 1% (5) | 1% (5) | |
Good | 19% (128) | 11% (49) | |
Very good | 21% (142) | 16% (71) | |
Excellent | 6% (39) | 5% (24) | |
Missing | 53% (355) | 66% (290) | |